Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
ACT Biopharma
San Francisco, California, United Stateszs.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
ACT Biotech developed highly targeted oral cancer therapeutics. Its lead candidate, telatinib, showed promising results in Phase 2 trials for advanced stomach cancer with improved progression-free survival. The company filed a Special Protocol Assessment with the FDA for a planned Phase 3 trial but has not reported further clinical progress since the early/mid 2010s.
Other pipeline assets included EDP‑317 and ACTB‑1011 targeting various kinases relevant to oncology.
The company was acquired after raising $12M from investors including Eddingpharm and NGN Capital.
No evidence of commercialized products or ongoing clinical programs as of May 2025.
- Therapeutic areas
- Oncology
- Modalities
- small molecules (oral therapeutics)
- Industry
- Biotech
02
Partnerships
Not specified; no major pharma partnerships publicly disclosed.
Beyond the preview
Go deeper on ACT Biopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ACT Biopharma.